Business
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
VENLO, Netherlands, March 31, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
About this update from Qiagen N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":242,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/20b32e21c1de5cd0e14ce70fe492c4ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UKJKIScl0UmgOXV8cxA59w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/20b32e21c1de5cd0e14ce70fe492c4ee","width":242,"height":204}},"lazy":false},{"type":"text","content":"VENLO, Netherlands, March 31, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.","length":374,"tagName":"p"},{"type":"text","content":"QIAGEN will provide printed copies of the 2024 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2024 Annual Report please use our contact form or send an email to [email protected].","length":219,"tagName":"p"},{"type":"text","content":"About QIAGEN","length":12,"tagName":"p"},{"type":"text","content":"QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.","length":932,"tagName":"p"},{"type":"text","content":"Forward-Looking Statement","length":25,"tagName":"p"},{"type":"text","content":"Certain statements in th...